Glioblastomas (GBM) are among the most aggressive and therapy-resistant tumors of the central nervous system and present both clinicians and researchers with immense challenges. Despite significant advances in diagnostics and an improvement in standard therapy, which usually consists of surgical resection, subsequent radiotherapy and the administration of temozolomide, the survival prospects are still unsatisfactory. This is mainly due to the pronounced resistance, the complex tumor heterogeneity and the immunomodulating properties of glioblastoma cells and their microenvironment.
You May Also Like
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Pain and autism